Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | F2 | P00734 | 3/20 | 0.59 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.59 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.59 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | EDNRA | P25101 | 10/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | NSD2 | O96028 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9019311 | 0.85 | CA2 (0.71) | CA2CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL13165739 | 0.83 | CDK2 (0.46) | CA2CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL109002 | 0.83 | CA2 (0.69) | CA2CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL10730548 | 0.83 | CA2 (0.69) | CA2CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL563863 | 0.83 | CA2 (0.69) | CA2CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL10344363 | 0.83 | CA2 (0.69) | CA2CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL21283 | 0.83 | CA2 (0.69) | CA2CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL11948494 | 0.83 | CA2 (0.69) | CA2CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL3116246 | 0.83 | CA2 (0.69) | CA2CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL133520 | 0.83 | CA2 (0.69) | CA2CYP1A2CYP2C19HTTHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023191549-A1 | FLUORESCENT PROBE FOR LABELING M1 MACROPHAGES, AND M1 MACROPHAGE MONITORING SYSTEM USING SAME | 기초과학연구원 | 2023-10-05 | — | — | WO | disclosed |
| EP-3405477-B1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2023-06-07 | — | — | EP | disclosed |
| US-20230056205-A1 | SUBSTITUTED 4,6-DIHYDROSPIRO[[1,2,3]TRIAZOLO[4,5-B]PYRIDINE-7,3'-INDOLINE]-2',5(3H)-DIONE ANALOGUES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-02-23 | — | — | US | disclosed |
| WO-2023016517-A1 | NAPHTHALENESULFONYL COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 复旦大学 | 2023-02-16 | — | — | WO | disclosed |
| US-20220213471-A1 | SMALL MOLECULE SCREENING CELLULAR ASSAY USING MODIFIED BEADS | F. HOFFMANN-LA ROCHE AG (CH) | 2022-07-07 | — | — | US | disclosed |
| US-11072634-B2 | Inhibitors of transglutaminases | ZEDIRA GMBH (DE) | 2021-07-27 | — | — | US | disclosed |
| US-20210169911-A1 | PURINE AND PYRIMIDINE NUCLEOTIDES AS ECTO-5'-NUCLEOTIDASE INHIBITORS | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-06-10 | — | — | US | disclosed |
| US-RE48510-E1 | Phosphorus functional antimicrobial coatings for metal surfaces | NANO SAFE COATINGS INCORPORATED (US) | 2021-04-13 | — | — | US | disclosed |
| US-20210047329-A1 | SUBSTITUTED 4,6-DIHYDROSPIRO[[1,2,3]TRIAZOLO[4,5-B]PYRIDINE-7,3'-INDOLINE]-2',5(3H)-DIONE ANALOGUES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-02-18 | — | — | US | disclosed |
| US-10808008-B2 | Aromatic-cationic peptides and uses of same | CORNELL UNIVERSITY (US) | 2020-10-20 | — | — | US | disclosed |
| EP-1501796-B1 | 3-(PYRIDINYL-AMINO)-1H-INDOLE-2-CARBOXYLIC ACID DERIVATIVES AS INTERLEUKIN-4 GENE EXPRESSION INHIBITORS | AVENTIS PHARMA INC (US) | 2007-05-09 | — | — | EP | disclosed |
| US-7214698-B2 | Beta-agonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-05-08 | — | — | US | disclosed |
| US-7202093-B2 | Method for labeling phosphorylated peptides, method for selectively adsorbing phosphorylated peptides, complex compounds used in the methods, process for producing the complex compounds, and raw material compounds for the complex compounds | KABUSHIKI KAISHA NARD KENKYUSHO (JP) | 2007-04-10 | — | — | US | disclosed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
| US-20070060754-A1 | Alkoxy substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-03-15 | — | — | US | disclosed |
| US-20070060754-A1 | Alkoxy substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-03-15 | — | — | US | disclosed |
| US-20070027144-A1 | Novel use of cannabinoid receptor agonist | SHIONOGI & CO., LTD. (JP) | 2007-02-01 | — | — | US | disclosed |
| US-7169925-B2 | Indole derivatives as interleukin-4 gene expression inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169925-B2 | Indole derivatives as interleukin-4 gene expression inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-7157454-B2 | Derivatives of n-(arylsulfonyl)beta-aminoacids comprising a substituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2007-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047329-A1 | SUBSTITUTED 4,6-DIHYDROSPIRO[[1,2,3]TRIAZOLO[4,5-B]PYRIDINE-7,3'-INDOLINE]-2',5(3H)-DIONE ANALOGUES | DHPS, QDPR, HTR5A | CA2 4007/4885CYP1A2 243/4885CYP2C19 1161/4885 |
| US-20230056205-A1 | SUBSTITUTED 4,6-DIHYDROSPIRO[[1,2,3]TRIAZOLO[4,5-B]PYRIDINE-7,3'-INDOLINE]-2',5(3H)-DIONE ANALOGUES | DHPS, QDPR, HTR5A | CA2 3968/4885CYP1A2 248/4885CYP2C19 1165/4885 |
| US-10808008-B2 | Aromatic-cationic peptides and uses of same | PDF, ARG2, NLN | CA2 2077/4885CYP1A2 4761/4885CYP2C19 4585/4885 |
| US-20070027144-A1 | Novel use of cannabinoid receptor agonist | CNR2, CNR1, OPRM1 | CA2 1856/4885CYP1A2 464/4885CYP2C19 571/4885 |
| US-20070060754-A1 | Alkoxy substituted imidazoquinolines | IL2, IFNG, IRF3 | CA2 4015/4885CYP1A2 1780/4885CYP2C19 2831/4885 |
| US-20210169911-A1 | PURINE AND PYRIMIDINE NUCLEOTIDES AS ECTO-5'-NUCLEOTIDASE INHIBITORS | NUDT1, NTPCR, NT5C2 | CA2 2118/4885CYP1A2 3563/4885CYP2C19 2959/4885 |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | CA2 3978/4885CYP1A2 1069/4885CYP2C19 3141/4885 |
| US-11072634-B2 | Inhibitors of transglutaminases | TGM2, TGM3, TGM1 | CA2 878/4885CYP1A2 948/4885CYP2C19 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.